Skip to main content
. Author manuscript; available in PMC: 2010 Oct 3.
Published in final edited form as: Cancer Res. 2008 Oct 15;68(20):8201–8209. doi: 10.1158/0008-5472.CAN-07-6567

Figure 5. Pard6b is overexpressed in estrogen receptor positive human breast tumors.

Figure 5

(A) Quantitative PCR analysis of Par6β gene expression using cDNA from breast cancer cell lines and normalized to GAPDH gene expression. Data is represented as fold increase over MCF-10A control cells. (B) Quantitative PCR analysis of Par6 β gene expression using cDNA generated from primary breast tumors and normalized to GAPDH gene expression. Data is represented as fold increase over the average levels expressed in normal breast tissue. (C) A box plot of the microarray data comparing Pard6b gene expression in ER− verses ER+ tumor samples. A Kolmogorov-Smirnov null hypothesis test was used to calculate the p-value (P = 2.9 × 10−7) (D) Hierarchical clustering from a supervised comparison between paired samples of normal TDLUs and HELUs. Pard6b is expressed 2.5 fold (P = 0.02) and PKCZ 1.46 fold (P = 0.029) in HELU compared to TDLU (40).